Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP / Peter A. Lio, MD - Targeting Interleukins to Improve Treatment Outcomes in Atopic Dermatitis

Go online to PeerView.com/FRX860 to view the activity, download
slides and practice aids, and complete the post-test to earn
credit. Atopic dermatitis (AD) is a chronic disease that affects a
significant portion of the US population. The current treatment
paradigm for AD is complex, involving multiple active drugs
tailored to different body parts, stages of the disease, and
severity levels, in addition to moisturizers, bathing practices,
and lifestyle recommendations. However, the effectiveness of
certain available treatment options is limited because of concerns
regarding efficacy, tolerability, and safety. In recent years,
there have been significant advancements in the treatment of AD,
including the approval of the first biologic agent and the ongoing
clinical development of targeted therapies. In this activity, a
panel of experts discuss the severity of AD across different
patient populations, considering the chronic and heterogeneous
nature of the disease, and the underlying pathophysiologic
processes that contribute to the development of AD. In addition,
they explore individualizing treatment for patients with moderate
to severe AD, with a goal of minimizing and preventing flares. Upon
completion of this activity, participants should be better able to:
Diagnose the severity of AD across different patient populations,
considering the chronic and heterogeneous nature of the disease;
Describe underlying pathophysiologic processes that contribute to
the development of AD, and provide rationale for the use of
targeted biologic therapy; and Select appropriate treatment for
patients with moderate to severe AD, including biologic agents as
appropriate, according to recent clinical evidence and current
guidelines, with a goal of minimizing/preventing flares